Nancy S. Lurker
Independent DirectorMs. Nancy S. Lurker is Director of Collegium Pharmaceutical, Inc. from February 4, 2025. Ms. Lurker is Independent Director at Alkermes plc since March 7, 2024. She serves as Director of NSF Health Sciences Ltd. since January 2024. She is Director at NSF International Inc from January 2024. She is recognized for her diverse experience in the pharmaceutical and biotechnology industries. She is on the board of directors of Altasciences, LLC and serves as an advisor for the Stanford School of Medicine's Master's in Translational Medicine program and Novo Holdings. She serves as a Member of Advisory Group at Novo Holdings A/S. She had been the Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.) since September 15, 2016 until July 10, 2023 and served as its President since September 15, 2016. Ms. Lurker served as the Chief Executive Officer of Interpace Diagnostics Group, Inc. (also known as PDI, Inc.) from November 11, 2008 to December 22, 2015 and its President from December 7, 2015 to December 22, 2015. She is an accomplished biopharmaceutical industry leader with many years of strategic, management and operational experience across all aspects of drug development and commercialization. She served as the Chief Marketing Officer of Novartis Pharmaceuticals Corporation since May 2006 until 2007 and served as its Senior Vice President of Marketing from 2006 to 2007. She is a many year veteran of the pharmaceutical industry. She served as the President and Chief Executive Officer of AlphaImpactRx, Inc. since 2003 until 2006. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products, Group Vice President of Global Prescription Business and Vice President, General Therapeutics for Pharmacia Corporation (now Pharmacia LLC), where she led a global business unit that commercialized urology, cardiovascular, central nervous system, respiratory and women’s health drugs, overseeing the worldwide launch of Detrol® and Detrol® LA and repositioning Ambien® for revenue growth. She served a number of leadership positions in global commercial management, marketing and strategic development with Bristol-Myers Squibb and National Physicians Corporation. She was Independent Director of Aquestive Therapeutics, Inc. from April 2018 until June 22, 2022. She held numerous positions in Marketing, Strategy, New Products and Sales. She spent many years at Bristol-Myers Squibb Company. She served as Chair of Board of Directors at X4 Pharmaceuticals Inc. since October 05, 2016 until July 2018. She had been a Director of EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.) since September 2016 until June 18, 2026 and served as its Vice Chairman from July 10, 2023 until June 18, 2026. She serves as a Member of the Novo Advisory Group. She served as a Senior Director at Worldwide Cardiovascular Franchise Management. Ms. Lurker was a Director of Cancer Treatment Centers of America, Inc. since February 05, 2016. She served as a Director of AlphaImpactRx, Inc. She served as a Director of PDI Inc from November 18, 2008 to December 22, 2015. She served as a Director of Auxilium Pharmaceuticals Inc. from June 2011 to January 29, 2015. She served as a Director of ConjuChem, LLC from 2004 to December 31, 2006. She served as a Non-Executive Director of Elan Corporation Limited from May 31, 2005 to May 31, 2006. Ms. Lurker served as a Director of Impactrx, Inc. She served as an Independent Director at Mallinckrodt public limited company since June 28, 2013 until July 21, 2016. She served as a Member of Diagnostics at BioNJ Inc. She earned a Bachelor of Science degree in Biology at Seattle Pacific University in Seattle, Washington and a Master of Business Administration degree at the University of Evansville in Evansville, Indiana.
Positions
- Company NameCollegium Pharmaceutical, Inc.Stock CodeCOLLPositionIndependent DirectorColleagues
- VKVikram KarnaniCEO, President & Director
- GSGino SantiniIndependent Chairman
- CTColleen TupperExecutive VP & CFO
- DDDavid DieterExecutive VP, General Counsel & Corporate Secretary
- TBThomas B. SmithExecutive VP & Chief Medical Officer
- IKIan KarpHead of Investor Relations
- GGGaren G. BohlinIndependent Director
- RJRita J. Balice-GordonIndependent Director
